PDCD1 and neoplasm: To further determine whether the administration sequence affects the efficacy of CX4945 combined with anti‐PD‐1 therapy, we utilized a TC‐1–OVA‐transplanted tumor mouse model known for its low response rate to anti‐PD‐1 therapy.